Trelegy Ellipta Powder
NDC Package 0173-0893-61
Package Information
Trelegy Ellipta (fluticasone furoate, umeclidinium bromide and vilanterol trifenatate) powders is tRELEGY ELLIPTA is contraindicated in the following conditions:•Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required [see Warnings and Precautions (5.2)].•Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone furoate, umeclidinium, vilanterol, or any of the excipients [see Warnings and Precautions (5.11), Description (11)]. This formulation utilizes a powder delivery system. Marketed by Glaxosmithkline Llc, this product is identified by NDC 0173-0893 and is authorized under FDA application NDA209482.
Identification & Billing
- RxCUI: 1945039 - fluticasone furoate 100 MCG/ACTUAT / umeclidinium 62.5 MCG/ACTUAT / vilanterol 25 MCG/ACTUAT Dry Powder Inhaler, 14 Blisters
- RxCUI: 1945039 - 14 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler
- RxCUI: 1945039 - fluticasone furoate 100 MCG/ACTUAT / umeclidinium (as umeclidinium Br) 62.5 MCG/ACTUAT / vilanterol (as vilanterol trifenatate) 25 MCG/ACTUAT Dry Powder Inhaler, 14 ACTUAT
- RxCUI: 1945044 - TRELEGY ELLIPTA 100 MCG / 62.5 MCG / 25 MCG Dry Powder Inhaler, 14 Blisters
- RxCUI: 1945044 - 14 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler [Trelegy]
Clinical Specifications
- Adrenergic beta2-Agonists - [MoA] (Mechanism of Action)
- Anticholinergic - [EPC] (Established Pharmacologic Class)
- Cholinergic Antagonists - [MoA] (Mechanism of Action)
- Corticosteroid Hormone Receptor Agonists - [MoA] (Mechanism of Action)
- Corticosteroid - [EPC] (Established Pharmacologic Class)
- beta2-Adrenergic Agonist - [EPC] (Established Pharmacologic Class)
Regulatory & Marketing
Hierarchy Structure
- 0173 - Glaxosmithkline Llc
- 0173-0893 - Trelegy Ellipta
- 0173-0893-61 - 1 TRAY in 1 CARTON / 1 INHALER in 1 TRAY / 14 POWDER in 1 INHALER
- 0173-0893 - Trelegy Ellipta
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0173-0893). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0173-0893-61 identifies a specific commercial package of 1 tray in 1 carton / 1 inhaler in 1 tray / 14 powder in 1 inhaler of Trelegy Ellipta, a human prescription drug labeled by Glaxosmithkline Llc. This powder is formulated for respiratory (inhalation) use and contains fluticasone furoate; umeclidinium bromide; vilanterol trifenatate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Glaxosmithkline Llc on September 09, 2020. The current certification is valid through December 31, 2027.
How is this Glaxosmithkline Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00173089361. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.